Details of the Drug Combination

General Information of Drug Combination (ID: DCQL98S)

Drug Combination Name
Indazole derivative 5 BIO-300
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs Indazole derivative 5   DMM1I8R BIO-300   DMJ7NVI
Small molecular drug N.A.
High-throughput Screening Result Testing Cell Line: SW-620
Zero Interaction Potency (ZIP) Score: 9.06
Bliss Independence Score: 5.2
Loewe Additivity Score: 0.89
LHighest Single Agent (HSA) Score: 4.82

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indazole derivative 5 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
ABL T315I mutant (ABL T315I) TTZJTWA ABL1_HUMAN Inhibitor [4]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) TTIV39N BCR_HUMAN-ABL1_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
Indication(s) of BIO-300
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
Rheumatoid arthritis FA20 Phase 1 [3]

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult T acute lymphoblastic leukemia DCVXFIO MOLT-4 Investigative [5]
Chronic myelogenous leukemia DCYEWT2 K-562 Investigative [5]
Clear cell renal cell carcinoma DCKK021 TK-10 Investigative [5]
Clear cell renal cell carcinoma DC5E3QL CAKI-1 Investigative [5]
Glioblastoma DCPWJ5V SNB-75 Investigative [5]
Glioma DCNOQ2A SF-539 Investigative [5]
Colon carcinoma DCX77FK KM12 Investigative [6]
Adenocarcinoma DCF9LRM HCC-2998 Investigative [1]
Amelanotic melanoma DCO560Z MDA-MB-435 Investigative [1]
Large cell lung carcinoma DC272VJ NCI-H460 Investigative [1]
Lung adenocarcinoma DCHNDU0 NCI-H522 Investigative [1]
Minimally invasive lung adenocarcinoma DCVJNI1 NCI-H322M Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Clinical pipeline report, company report or official report of Humanetics.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
5 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
6 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.